ABVD regimen: Difference between revisions
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AV}} | {{CMG}}; {{AE}} {{AV}} | ||
{{SK}} | {{SK}} ABVD; ABVD regimen; Adriamycin-Bleomycin-Vinblastine-Dacarbazine regimen; BLEO/DOX/DTIC/VBL; Bleomycin/Dacarbazine/Doxorubicin/Vinblastine regimen | ||
Adriamycin-Bleomycin-Vinblastine-Dacarbazine | |||
BLEO/DOX/DTIC/VBL | |||
Bleomycin/Dacarbazine/Doxorubicin/Vinblastine | |||
regimen | |||
==Overview== | ==Overview== | ||
Line 17: | Line 9: | ||
==Regimen== | ==Regimen== | ||
[[Doxorubicin|{{button| | [[Doxorubicin|{{button|A – Doxorubicin ((Adriamycin))}}]] | ||
[[Bleomycin|{{button|B – Bleomycin}}]] | [[Bleomycin|{{button|B – Bleomycin}}]] | ||
Line 27: | Line 19: | ||
==Indications== | ==Indications== | ||
* Primary treatment of [[Hodgkin lymphoma | * Primary treatment of [[Hodgkin's lymphoma]] <ref name="pmid25016811">{{cite journal| author=Nagai H| title=[Hodgkin lymphoma]. | journal=Nihon Rinsho | year= 2014 | volume= 72 | issue= 6 | pages= 1099-103 | pmid=25016811 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25016811 }} </ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Chemotherapy regimens]] | [[Category:Chemotherapy regimens]] |
Revision as of 15:43, 27 February 2015
WikiDoc Resources for ABVD regimen |
Articles |
---|
Most recent articles on ABVD regimen Most cited articles on ABVD regimen |
Media |
Powerpoint slides on ABVD regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on ABVD regimen at Clinical Trials.gov Clinical Trials on ABVD regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on ABVD regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on ABVD regimen Discussion groups on ABVD regimen Patient Handouts on ABVD regimen Directions to Hospitals Treating ABVD regimen Risk calculators and risk factors for ABVD regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for ABVD regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: ABVD; ABVD regimen; Adriamycin-Bleomycin-Vinblastine-Dacarbazine regimen; BLEO/DOX/DTIC/VBL; Bleomycin/Dacarbazine/Doxorubicin/Vinblastine regimen
Overview
ABVD regimen refers to an a chemotherapy regimen consisting of doxorubicin hydrochloride (Adriamycin), bleomycin, vinblastine and dacarbazine, used alone or in combination with radiation therapy, for the primary treatment of Hodgkin lymphoma.[1][2]
Regimen
A – Doxorubicin ((Adriamycin))
Indications
- Primary treatment of Hodgkin's lymphoma [3]
References
- ↑ "NCI Thesaurus".
- ↑ "R-CHOP - National Cancer Institute".
- ↑ Nagai H (2014). "[Hodgkin lymphoma]". Nihon Rinsho. 72 (6): 1099–103. PMID 25016811.